Bicocca Open Archive

Logo unimib boa
FAGIUOLI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.704
EU - Europa 5.849
AS - Asia 1.514
SA - Sud America 29
Continente sconosciuto - Info sul continente non disponibili 15
AF - Africa 9
OC - Oceania 7
Totale 16.127
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.547
IE - Irlanda 1.750
IT - Italia 1.209
DE - Germania 1.109
SE - Svezia 984
HK - Hong Kong 745
CN - Cina 419
IN - India 220
GB - Regno Unito 210
UA - Ucraina 185
CA - Canada 153
FI - Finlandia 77
NL - Olanda 50
RU - Federazione Russa 46
DK - Danimarca 45
FR - Francia 45
VN - Vietnam 40
AT - Austria 33
BE - Belgio 28
ES - Italia 20
SG - Singapore 20
TR - Turchia 19
BR - Brasile 14
IR - Iran 14
EU - Europa 12
PL - Polonia 12
KR - Corea 11
CL - Cile 8
JP - Giappone 7
RO - Romania 7
CH - Svizzera 6
TW - Taiwan 6
GR - Grecia 5
NO - Norvegia 5
AU - Australia 4
CZ - Repubblica Ceca 4
EG - Egitto 4
MM - Myanmar 4
BG - Bulgaria 3
EE - Estonia 3
NZ - Nuova Zelanda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AR - Argentina 2
CO - Colombia 2
LY - Libia 2
MD - Moldavia 2
PA - Panama 2
PT - Portogallo 2
A1 - Anonimo 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BO - Bolivia 1
DZ - Algeria 1
EC - Ecuador 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
IL - Israele 1
IM - Isola di Man 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LT - Lituania 1
ME - Montenegro 1
MU - Mauritius 1
PK - Pakistan 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
VE - Venezuela 1
Totale 16.127
Salva come PNG Salva come JPEG
Città #
Dublin 1.701
Ann Arbor 1.271
Frankfurt am Main 936
Princeton 886
New York 737
Hong Kong 736
Fairfield 672
Chandler 662
Ashburn 654
Woodbridge 462
Houston 439
Lawrence 327
Altamura 321
Milan 300
Wilmington 300
Cambridge 249
Seattle 239
Jacksonville 163
San Diego 160
Pune 156
Dearborn 143
Shanghai 94
Andover 89
Toronto 75
London 64
Nanjing 59
Washington 53
Beijing 50
Rome 44
Hangzhou 39
Fremont 37
Boardman 34
Helsinki 33
Los Angeles 33
Vienna 31
Guangzhou 30
Lachine 28
Chicago 24
Ottawa 24
Brussels 21
Shenyang 21
Huizen 20
Tianjin 20
Cedar Knolls 18
Dong Ket 18
Kilburn 17
Bergamo 15
Esslingen am Neckar 15
Lappeenranta 14
Norwalk 14
Boston 13
Manchester 12
Monza 12
Nanchang 12
San Mateo 12
Turin 12
Umeå 12
Falls Church 11
Padova 11
Singapore 11
Jinan 10
Mountain View 10
Groningen 9
Bonndorf 8
Catania 8
Hounslow 8
Modena 8
Central 7
Hebei 7
Hyderabad 7
Mumbai 7
Naples 7
Ningbo 7
Phoenix 7
São Paulo 7
Bologna 6
Brescia 6
Nürnberg 6
Tappahannock 6
Warsaw 6
Carate Brianza 5
Changsha 5
Florence 5
Indianapolis 5
Inzigkofen 5
Jiaxing 5
Montréal 5
Oslo 5
Paris 5
Redmond 5
Southwark 5
Valencia 5
Valmadrera 5
Vigevano 5
Chiari 4
Coimbatore 4
Easton 4
Edmonton 4
Elmont 4
Ferrara 4
Totale 12.907
Salva come PNG Salva come JPEG
Nome #
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 277
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 212
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 185
HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy 175
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 171
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 170
Health Related Quality of Life in the Major Liver Conditions 169
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 167
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 166
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 164
Health related quality of life in chronic liver diseases 163
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 159
The impact of liver disease on the health-related quality of life 159
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 157
High rates of 30-day mortality in patients with cirrhosis and COVID-19 155
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 154
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 149
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 149
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 148
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis 147
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching 146
Balancing donor and recipient risk factors in liver transplantation: The value of D-MELD with particular reference to HCV recipients 142
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 139
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list 137
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 134
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 133
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 133
Combined double lung-liver transplantation for cystic fibrosis without cardio-pulmonary by-pass. 129
Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria 128
Treatment of hepatocellular carcinoma: A cost analysis of yttrium-90 transarterial radioembolization versus sorafenib 128
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 126
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 123
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study 122
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 121
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 120
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 119
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 119
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 118
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 118
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 116
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 115
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 115
A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study 114
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 114
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 110
The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): A post-hoc between-sex analysis 108
HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation 96
Safety and Efficacy of Subcutaneous Hepatitis B Immunoprophylaxis using “on demand” Approach: A Single Center Experience 94
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 94
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 91
Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness 91
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 87
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients 84
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 81
Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis 80
Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study 79
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 78
COVID-19: role of resilience on the psychological impact of lockdown in liver transplant transitional candidates and recipients COVID-19: ruolo della resilienza sull’impatto psicologico del lockdown nei candidati e nei riceventi del trapianto di fegato (adolescenti-giovani adulti) 77
Selective use of ex-situ machine perfusion after normothermic regional perfusion in liver transplantation from donation after circulatory death 76
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 73
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 72
Location and allocation: inequity of access to liver transplantation for patients with severe acute‐on‐chronic liver failure in Europe 72
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 71
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19” 67
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 67
The societal burden of chronic liver diseases: Results from the COME study 65
Safety and Efficacy of Subcutaneous Hepatitis B Immunoprophylaxis using" on demand" Approach: A Single Center Experience 62
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 59
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 59
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation 55
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 54
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 54
Prevalent use of Combined Prophylaxis of Hepatitis B after liver transplantation in Italy: Results of a national survey in a large cohort 52
Calcio libero citoplasmatico e citotossicita' in epatociti sottoposti ad anossia 52
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 51
Meet–Test–Treat for HCV management: patients’ and clinicians’ preferences in hospital and drug addiction services in Italy 51
Physiological reno-portal bypass in liver transplantation with non-tumorous portal vein thrombosis 50
Bergamo and Covid-19: How the Dark Can Turn to Light 50
Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study 50
Il nuovo immunodepressore FK 506 modula il danno acuto da D galattosamina nel ratto 50
Citolisi e colestasi post-oltx per cirrosi HCV: l’enigma della diagnosi differenziale 49
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 49
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 48
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation 48
EVIDENCE FOR EPITHELIAL-MESENCHYMAL TRANSITION IN HUMAN CHOLANGIOCARCINOMA 47
Use of Everolimus in Liver Transplantation: Recommendations from a Working Group 46
The use of molecular assays in the management of viral hepatitis 46
Prophylaxis and treatment of hepatitis B in immunocompromised patients 46
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 46
Evidence for biliary epithelial to mesenchymal transition in human cholangiocarcinoma 45
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 44
Plasma fibronectin in acute and chronic liver diseases [FIBRONECTINA PLASMATICA NELLE EPATOPATIE ACUTE E CRONICHE. VALIDITA DELL'ANALISI QUANTITATIVA] 44
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 43
Strategie terapeutiche nella gestione del paziente con epatite cronica HCV-correlata 43
The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience 43
Hormonal treatment of hepatocellular carcinoma 43
Risk of hepatocellular carcinoma in alcoholic cirrhosis 43
Le epatiti croniche: inquadramento nosografico 43
Storia naturale dell'epatite cronica persistente (ECP) HBsAg positiva 43
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting 42
Totale 9.868
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.239
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.239
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019248 0 0 0 0 0 0 0 0 0 0 111 137
2019/20201.329 156 70 88 100 108 168 163 111 132 96 95 42
2020/20211.419 61 62 158 134 123 123 134 162 120 118 79 145
2021/20223.656 81 115 168 213 68 155 43 1.395 86 314 245 773
2022/20235.072 798 1.485 460 295 306 871 64 292 218 61 150 72
2023/20244.464 74 128 152 226 754 1.452 973 162 461 73 9 0
Totale 17.686